AnaptysBio, Inc. ANAB
At closeNov 5, 2026, 4:00 PM EST
After hours · Nov 5, 4:00 PM ET
Day range unavailable
- YTD
- +41.03%
- 1 year
- +89.92%
- Market cap
- 1.36B
- Revenue (ttm)
- 106.09M
- Profit margin
- 246.96%
- EPS (ttm)
- -0.96
- Shares out
- 29.90M
- Forward P/E
- 10.05
- YTD return
- +41.03%
- 1-year return
- +89.92%
- Avg volume
- 487.01K
- Previous close
- 45.58
- 52-week range
- 20.18 – 72.36
- Beta
- 0.37
- Analysts
- Strong Buy
- Price target
- 87.25 (+91.4%)
- Earnings date
- Nov 3, 2026
5D -5.43 (-10.64%)
Key statistics
- Enterprise value
- 1.53B
- PEG ratio
- 0.00
- Price / sales
- 12.86
- Price / book
- 128.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 23.50%
- Free cash flow
- 0
- Total cash
- 164.14M
- Total debt
- 269.59M
- Return on equity
- 0.00%
- Short % of float
- 39.67%
- 50-day average
- 51.11
- 200-day average
- 50.65
Analyst view
Consensus: strong buy
- Target (low)
- 60.00
- Target (mean)
- 87.25
- Target (high)
- 140.00
- Strong buy3
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate 0.53088.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -1.84 | — | — | — |
| Sep 21, 2026 | Jun 30, 2026 | 5.11 | 5.11 | 0.00 | 0.00% |
| May 12, 2026 | Mar 31, 2026 | -0.32 | -1.84 | -1.52 | -475.00% |
| Mar 3, 2026 | Dec 31, 2025 | 0.89 | 1.58 | +0.69 | +77.53% |
| Nov 4, 2025 | Sep 30, 2025 | -1.06 | 0.52 | +1.58 | +149.06% |
| Aug 7, 2025 | Jun 30, 2025 | -1.50 | -1.34 | +0.16 | +10.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 2026 | JP Morgan | main | Overweight | Overweight |
| Sep 24, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 23, 2026 | Leerink Partners | main | Outperform | Outperform |
| Aug 25, 2026 | TD Cowen | main | Buy | Buy |
| Aug 24, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| May 13, 2026 | UBS | main | Buy | Buy |
About AnaptysBio, Inc.
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- anaptysbio.com
News
Riverwater Micro Opportunities Strategy Q3 2026 Portfolio Activity 
JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $60 
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target 
Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81 
12 Health Care Stocks Moving In Monday's After-Market Session - AnaptysBio Q2 Adj. EPS $(0.11) Beats $(0.46) Estimate, Sales $27.488M Beat $21.675M Estimate
- TD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target 
FedEx, Cerebras Systems And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session 
HC Wainwright & Co. Assumes AnaptysBio at Buy, Announces Price Target of $95
Your note
Sign in to keep a note on ANAB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ECOR1 CAPITAL, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 1, 2025 | 0 |
| FAGA DANIEL R | Chief Executive Officer | Sale | Mar 26, 2026 | 495,965 |
| JAIN RITA | Director | Conversion of Exercise of derivative security | Jun 12, 2025 | 11,864 |
| LIZZUL PAUL F. | Officer | Sale | Jan 7, 2026 | 42,088 |
| LOUMEAU ERIC JOSEPH | Officer | Sale | Feb 10, 2026 | 12,835 |
| MARQUET MAGDA | Director | Sale | Jan 14, 2026 | 9,930 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 26.36% | 7,880,094 | 359.57M | Jun 29, 2026 |
| Blackrock Inc. | 6.17% | 1,844,049 | 84.14M | Jun 29, 2026 |
| Tang Capital Management, LLC | 4.45% | 1,330,879 | 60.73M | Jun 29, 2026 |
| State Street Corporation | 4.30% | 1,286,194 | 58.69M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.03% | 906,233 | 41.35M | Jun 29, 2026 |
| Affinity Asset Advisors, Llc | 2.76% | 826,109 | 37.70M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.17% | 648,146 | 29.57M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.14% | 640,363 | 29.22M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.75% | 522,209 | 23.83M | Sep 29, 2026 |
| TIAA-CREF Funds-Nuveen Quant Small Cap Equity Fund | 0.88% | 263,840 | 12.04M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.79% | 237,032 | 10.82M | Jun 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.72% | 215,697 | 9.84M | Sep 29, 2026 |